Sanofi (NASDAQ:SNY) will begin shipping Beyfortus (nirsevimab) in early Q3 to ensure widespread availability ahead of the ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June ...

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...

RSV is responsible for around 1 lakh deaths, over 3.6 million hospitalisations in children under age of 5 every year, ...

New prevention measures for RSV have led to a major drop in hospitalizations among infants, according to a new CDC study.

The announcement comes as part of WHO’s broader effort to reduce child mortality, particularly in low- and middle-income ...

Respiratory syncytial virus (RSV) is the number one cause of hospitalization in infants, accounting for about 25% of all ...

For Perth mum Katherine, life with a newborn was meant to be filled with cuddles and milestones. Her baby then caught what ...

Universal immunisation with nirsevimab significantly reduces hospitalizations and paediatric intensive care admissions for ...

A statewide immunization program for infants against respiratory syncytial virus (RSV), which began in 2024, has already ...

Experts say new immunisation program working, but some babies missing outThe number of Australian babies admitted to hospital ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early ...